A two-year-long discovery chemistry collaboration between Charnwood Molecular and Forendo Pharma has seen compounds move from discovery to pre-clinical development.
Charnwood Molecular and Forendo Pharma have been collaborating since September 2015, with Charnwood Molecular synthesising challenging steroidal analogues of a hit compound initially identified at Forendo Pharma. Multi-centred lead optimisation efforts led to the identification of a development candidate, for which Charnwood Molecular’s pre-clinical Process Development group scouted various routes for larger-scale synthesis. Studied processes initially delivered multi-gram quantities within the collaboration, before being used by Forendo Pharma to access multi-kilogram quantities of the compound they are now progressing into development.
Dr Robin Wilkes, Director of Business Development at Charnwood Molecular commented: ‘Charnwood Molecular is being increasingly engaged by small companies looking to quickly progress pre-clinical assets into drug development. The infrastructure and partnerships we have developed over the past few years now allow us to do that. We have thoroughly enjoyed working alongside such an excellent collaborator as Forendo Pharma, who we wish every success in taking their development candidates forward’.
“Charnwood Molecular was consistently solving difficult synthetic routes and achieving good results, bringing new ideas and delivering all expectations” added T. Linnanen, Forendo Pharma, Head of Drug Discovery.
About Forendo Pharma
Forendo Pharma is a drug development company that specialises in diseases associated with tissue specific hormone mechanisms. The company is a world-leading innovator in the endometriosis field, with two active programs. Fispemifene, which was developed as part of the company’s men’s health program, is currently used in clinical practice for the treatment of male urological conditions. For further information about Forendo Pharma please see: www.forendo.com
About Charnwood Molecular
Charnwood Molecular is a leading CRO providing Drug Discovery and early, pre-clinical Development services. Founded in 1998, we support the Drug Discovery activities of organisations from virtual start-ups to large Pharmaceutical companies. We offer a flexible service from the synthesis of single compounds to the full management of Medicinal Chemistry projects. For further information about Charnwood Molecular please see: www.charnwood-molecular.com